Lexaria Bioscience CorpLEXX
Price$3.09Intrinsic value$1.4753% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $194K-14.2% YoYTTM through 31 May 2026
Net Income -$7.7MTTM through 31 May 2026
Free Cash Flow -$7.5MTTM through 31 May 2026

Margins

Current
Operating Margin-3,973.2%
Net Margin-3,985.6%

Returns

-163.2%ROE
-161.7%ROA

Balance Sheet Health

Current Ratio10.61x
Net Debt-$3.4Mnet cash position
Cash & Equivalents$3.5M

Quality Metrics

Altman Z-Score69.97
Piotroski F-Score3 / 9
FCF Margin-3,848.6%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25
FY2025: $705.9K
Diluted EPS-$0.34TTM
'10'11'23'24'25
FY2025: $-0.66

Dividend

No dividend

Capital Allocation

Capex Intensity21.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.